SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    North American Association of Central Cancer Registries. http://www.naacr.org/data, 1999.
  • 2
    Australian Institute of Health & Welfare. http://www.aihw.gov.au/publications/health/html, 1999.
  • 3
    Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991; 5: 21452154.
  • 4
    Edwards DR, Murphy G. Cancer. Proteases—invasion and more. Nature 1998;394: 527528.
  • 5
    Shapiro SD. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr Opin Cell Biol 1998; 10: 602608.
  • 6
    Birkedal-Hansen H, Moore WGI, Bodden MK, et al. Matrix metalloproteinases: A Review. Crit Rev Oral Biol Med 1993; 4: 197250.
  • 7
    Nagase H, Okada Y. Proteinases and Matrix Degradation. In: KelleyWN, HarrisED, RuddyS, SledgeWB, editors. Textbook of rheumatology. Philadelphia: W.B Saunders, 1997: 32341.
  • 8
    Greene J, Wang M, Liu YE, Raymond LA, Rosen C, Shi YE. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem 1996; 271: 3037530380.
  • 9
    Apte SS, Olsen BR, Murphy G. The gene structure of tissue inhibitor of metalloproteinases (timp)-3 and its inhibitory activities define the distinct timp gene family. J Biol Chem 1995; 270: 1431314318.
  • 10
    Ray JM, Stetler-Stevenson WG. The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 1994; 7: 20622072.
  • 11
    Butler GS, Butler MJ, Atkinson SJ, et al. The TIMP2 membrane type 1 metalloproteinase “receptor” regulates the concentration and efficient activation of progelatinase A. J Biol Chem 1998; 273: 871880.
  • 12
    Leco KJ, Khokha R, Pavloff N, Hawkes SP, Edwards DR. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem 1994; 269: 93529360.
  • 13
    Ray JM, Stetler-Stevenson WG. The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 1994; 7: 20622072.
  • 14
    Nomura H, Fujimoto N, Seiki M, Mai M, Okada, Y. Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas. Int J Cancer 1996;69: 916.
  • 15
    Maeta H, Ohgi S, Terada T. Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas. Virchows Arch 2001; 438: 121128.
  • 16
    Jones JL, Glynn P, Walker RA. Expression of MMP-2 and MMP-9, their inhibitors and the activator MT1-MMP in primary breast carcinomas. J Pathol 1999; 189: 161168.
  • 17
    Sakata K, Shigemasa K, Nagai N, Ohama K. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol 2000; 17: 673681.
  • 18
    Ueno H, Nakamura H, Inoue M, et al. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res 1997; 57: 20552060.
  • 19
    Nakamura H, Ueno H, Yamashita K, et al. Enhanced production and activation of progelatinase A mediated by membrane-type I matrix metalloproteinase in human papillary thyroid carcinomas. Cancer Res 1999; 59: 467– 473.
  • 20
    Määtta M, Soini Y, Liakka A, Autio-Harmainen H. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clin Cancer Res 2000; 6: 27262734.
  • 21
    Soini Y, Alarakkola E, Autio-Harmainen H. Expression of messenger RNAs for metalloproteinases 2 and 9, type IV collagen, and laminin in nonneoplastic and neoplastic endometrium. Hum Pathol 1997; 28: 220226.
  • 22
    Iurlaro M, Loverro G, Vacca A, et al. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with upgrading and myometrial invasion in endometrial carcinoma. Eur J Clin Invest 1999; 29: 793801.
    Direct Link:
  • 23
    Inoue Y, Abe K, Obata K, et al. Immunohistochemical studies on matrix metalloproteinase-9 (MMP-9) and type IV collagen in endometrial carcinoma. J Obstet Gynaecol Res 1997; 23: 139145.
  • 24
    Sato H, Takino T, Okada Y, et al. A matrix metalloprotease expressed on the surface of invasive tumour cells. Nature 1994; 370: 6165.
  • 25
    Nomura H, Sato H, Seiki M, Mai M, Okada Y. Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res 1995; 55: 32633266.
  • 26
    Määtta, M, Soini Y, Liakka A, Autio-Harmainen H. Localization of MT1-MMP, TIMP-1, TIMP-2, and TIMP-3 messenger RNA in normal, hyperplastic, and neoplastic endometrium. Am J Clin Pathol 2000;114: 402411.
  • 27
    Sakamoto H, Kinoshita K, Nakayama Y, et al. Gene expression in primary, metastatic and recurrent lesions of endometrial cancer. Gynecol Obstet Invest 1999; 48: 215220.
  • 28
    Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M, Okada A. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 1997; 272: 24462451.
  • 29
    d'Ortho M, Stanton H, Butler M, Atkinson SJ, Murphy G, Hembry RM. MT1-MMP on the cell surface causes focal degradation of gelatin films. FEBS Letters 1998; 421: 159164.
  • 30
    Sugiura Y, Shimada H, Seeger RC, Laug WE, DeClerck YA. Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis. Cancer Res 1998; 58: 22092216.
  • 31
    Rao JS, Yamamoto M, Mohaman S, et al. Expression and localization of 92 kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas. Clin Exp Metastasis 1996; 14: 1218.
  • 32
    Still K, Robson CN, Autzen P, Robinson MC, Hamdy FC. Localization and quantification of mRNA for matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in human benign and malignant prostatic tissue. Prostate 2000; 42: 1825.
  • 33
    Hoyhtya M, Fridman R, Komarek D, et al. Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. Int J Cancer 1994; 56: 500505.
  • 34
    Jeziorska M, Nagase H, Salamonsen LA, Woolley DE. Immunolocalisation of the matrix metalloproteinases gelatinase B and stromelysin 1 in human endometrium throughout the menstrual cycle. J Reprod Fertil 1996; 107: 4351.
  • 35
    Zhang J, Hampton AL, Nie G, Salamonsen LA. Progesterone inhibits activation of latent matrix metalloproteinase (MMP)-2 by membrane-type 1 MMP: enzymes coordinately expressed in human endometrium. Biol Reprod 2000; 62: 8594.
  • 36
    Shimada T, Nakamura H, Yamashita K, et al. Enhanced production and activation of progelatinase A mediated by membrane-type I matrix metalloproteinase in human oral squamous cell carcinomas: implications for lymph node metastasis. Clin Exp Metastasis 2000; 18: 179188.
  • 37
    Furuya M, Ishikura H, Nemori R, Shibata M, Fujimoto S, Yoshiki T. Clarification of the active gelatinolytic sites in human ovarian neoplasms using in situ zymography. Hum Pathol 2001; 32: 163168.
  • 38
    Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993; 9: 541573.
  • 39
    Levi E, Fridman R, Miao HQ, Ma YS, Yayon A, Vlodavsky I. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci USA 1996; 93: 70697074.
  • 40
    Gearing AJ, Beckett P, Christodoulou M, et al. Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 1994; 370: 555557.
  • 41
    Suzuki M, Raab G, Moses MA, Fernandez CA, Klagsbrun M. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J Biol Chem 1997; 272: 3173031737.
  • 42
    Zhang J, Salamonsen LA. Tissue inhibitor of metalloproteinases (TIMP)-1, -2 and -3 in human endometrium during the menstrual cycle. Mol Hum Reprod 1997; 3: 735741.
  • 43
    Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K. Growth-promoting activity of tissue inhibitor of metalloproteinase-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 1992;298: 2932.
  • 44
    Hayakawa T, Yamashita K, Ohuchi E, Shinagawa A. Cell growth-promoting activity of tissue inhibitor of metalloproteinase-2 (TIMP-2). J Cell Sci 1994; 107: 23732379.
  • 45
    Li G, Fridman R, Kim HR. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res 1999; 59: 62676275.
  • 46
    Goldberg GI, Strongin A, Collier IE, Genrich LT, Marmer BL. Interaction of 92kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenases and activation of the proenzyme with stromelysin. J Biol Chem 1992; 267: 45834591.
  • 47
    Murphy G, Willenbrock F, Ward RV, Cockett MI, Eaton D, Docherty AJ. The C-terminal domain of 72kDa gelatinase A is not required for catalysis, but is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases. Biochem J 1992; 283: 637641.
  • 48
    Kleiner DE Jr., Tuuttila A, Tryggvason K, Stetler-Stevenson WG. Stability analysis of latent and active 72-kDa type IV collagenase: the role of tissue inhibitor of metalloproteinases-2 (TIMP-2). Biochemistry 1993;32: 15831592.